If the blockbuster medicine is now a thing of the past, what does the future look like?




The latest edition of Pharmaphorum’s Deep Dive magazine “Future Pharma” focuses on the predictions for healthcare and the drug development process as pharma’s model is increasingly disrupted. 





The feature article written by our CEO, Chris Molloy, explains why the future of medical innovation lies with the industry’s SMEs:

“We are familiar with the industry noise around falling productivity and return on investment in pharma R&D. We are less familiar with hearing the call of the small and medium-sized enterprise (SME) community.

With help, I believe this group can quietly develop the greatest explosion in ‘new’ biology in 50 years. Traditionally the agile, risk-taking testers of new ideas, primed to be bought and incorporated into bigger firms or to see their products developed by others, SMEs now have a new opportunity: to grow and conquer.”

Read the full article in Future Pharma online

 







Other News

new board appointments
News
15 September 2026
Medicines Discovery Catapult appoints global life science and commercialisation leaders to its Board of Directors

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.


News
10 September 2026
Inspiring the next generation: Medicines Discovery Catapult scientist contributes to children’s science book 

Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.


News
03 September 2026
Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.





Medicines Discovery Catapult